Milvexian for the Prevention of Venous Thromboembolism

• Published in: The New England journal of medicine Vol. 385; no. 23; pp. 2161 - 2172
• Main Authors: Weitz, Jeffrey I, Strony, John, Ageno, Walter, Gailani, David, Hylek, Elaine M, Lassen, Michael R, Mahaffey, Kenneth W, Notani, Ravi S, Roberts, Robin, Segers, Annelise, Raskob, Gary E
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 02.12.2021
• Subjects: Administration, Oral; Adverse events; Aged; Aged, 80 and over; Anticoagulants; Anticoagulants - adverse effects; Anticoagulants - therapeutic use; Anticoagulation; Arthroplasty (knee); Arthroplasty, Replacement, Knee; Asymptomatic; Bleeding; Cardiology; Coagulation; Critical Care; Dose-Response Relationship, Drug; Drug dosages; Enoxaparin - adverse effects; Enoxaparin - therapeutic use; Factor XIa - antagonists & inhibitors; Female; Hematology; Humans; Joint replacement surgery; Joint surgery; Laboratories; Male; Middle Aged; Oncology; Orthopedics; Orthopedics General; Patients; Postoperative Complications - prevention & control; Pulmonary; Pulmonary embolisms; Surgery; Surgery General; Thromboembolism; Thrombosis; Veins & arteries; Venous Thromboembolism - prevention & control
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2113194

A phase 2 trial compared various doses of milvexian with standard enoxaparin for thromboprophylaxis after total knee replacement. Venous thromboembolism occurred in 7 to 8% of patients who received 200 mg of milvexian once or twice daily and in 21% of those who received enoxaparin. The risk of bleeding was similar with milvexian and enoxaparin.